1 Correction to: BioDrugs 2018; 32 (1): 91–98. https://doi.org/10.1007/s40259-018-0259-4
Page 91, abstract, lines 1–6: The following sentence, which previously read:
Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) [Abasaglar® (EU); Basaglar® (USA)] has been approved in the EU as a biosimilar to reference insulin glargine (Lantus®), and in the USA as a follow-on biologic to reference insulin glargine, for use in patients with type 1 or 2 diabetes.
should read:
Subcutaneous once-daily LY2963016 insulin glargine 100 U/mL (LY insulin glargine) [Abasaglar® (EU); Basaglar® (USA)] has been approved in the EU as a biosimilar to insulin glargine 100 U/mL (Lantus®) [reference insulin glargine], and in the USA as a follow-on biologic to reference insulin glargine, for use in patients with type 1 or 2 diabetes.
Pages 91-2, section 1, paragraph 1, lines 4–10: The following sentence, which previously read:
Subcutaneous once-daily insulin glargine 100 U/mL (Lantus®) is an established effective and well-tolerated basal insulin therapy in patients with type 1 or 2 diabetes [1]. Following the recent expiration of patents for insulin glargine, biosimilars of insulin glargine developed by other pharmaceutical companies are beginning to enter highly regulated markets [1, 2].
should read:
Subcutaneous once-daily insulin glargine 100 U/mL (Lantus®) [reference insulin glargine] is an established effective and well-tolerated basal insulin therapy in patients with type 1 or 2 diabetes [1]. Following the recent expiration of patents for reference insulin glargine, biosimilars of insulin glargine developed by other pharmaceutical companies are beginning to enter highly regulated markets [1, 2].
Page 92, section 1, paragraph 2, lines 1–4: The following sentence, which previously read:
Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) 100 U/mL [Abasaglar® (EU); Basaglar® (USA)] is a long-acting insulin analogue that is biosimilar to reference insulin glargine 100 U/mL.
should read:
Subcutaneous once-daily LY2963016 insulin glargine 100 U/mL [Abasaglar® (EU); Basaglar® (USA)] (LY insulin glargine) is a long-acting insulin analogue that is biosimilar to reference insulin glargine.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lamb, Y.N., Syed, Y.Y. Correction to: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes. BioDrugs 32, 181 (2018). https://doi.org/10.1007/s40259-018-0269-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-018-0269-2